Increased Expression of a Disintegrin and Metalloprotease-9 in Hepatocellular Carcinoma: Implications for Tumor Progression and Prognosis

Tao, Kaishan; Qian, Niansong; Tang, Yu; Ti, Zhenyu; Song, Wenjie; Cao, Deliang; Dou, Kefeng

doi:10.1093/jjco/hyq030

Cited by 35 publications

(26 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, a significant increase in ADAM9 protein expression in OSCC tissues, compared with in normal oral tissues, was demonstrated by immunohistochemistry, a finding that agrees with the results of other prior studies, which demonstrated ADAM9 protein overexpression in various types of cancer (9,15,17,18,(20)(21)(22)(23)25,26). Though particularly in squamous cell carcinoma, ADAM9 protein overexpression is also present in cancer of the cervix, the esophagus, the pharynx, the larynx, and the skin around the head and neck region (9,21,25,26).…”

Section: Discussionsupporting

confidence: 92%

“…Therefore, ADAM9 can function in both physiological and pathological conditions. Regarding its involvement in pathologic conditions, ADAM9 overexpression has been identified in a variety of cancer types, including breast cancer (16), renal cancer (17), prostate cancer (18), skin melanoma (19), uterine cervical cancer (20,21), hepatocellular carcinoma (22), non-small cell lung cancer (23), colon cancer (24), gastric cancer (15), esophageal cancer (25) and head and neck squamous cell carcinoma (HNSCC) (26). In the oral cavity, conflicting results of chromosomal aberrations in the ADAM9-containing region have been identified by the array comparative genomic hybridization technique (9,27).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Overexpression of ADAM9 in oral squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. Overexpression of a disintegrin and metalloproteinase 9 (ADAM9) has been shown in various types of cancer. Some studies have reported inconclusive findings regarding chromosomal aberrations in the ADAM9-containing region and ADAM9 expression in oral cancer. Therefore, in this study, ADAM9 protein expression was determined and compared between oral squamous cell carcinoma (OSCC) and normal oral tissues, and between oral cancer cell lines and human oral keratinocytes (HOKs). In total, 34 OSCC and 10 healthy paraffin-embedded tissue sections were probed with an anti-ADAM9 antibody, and the immunohistochemical score was determined by multiplying the percentage of positively stained cells with the intensity score. Four different oral cancer and eight independent HOK cell lines were cultured, and the expression of membrane ADAM9 and active ADAM9 at 84 kDa in these cell lines was assayed by flow cytometry and western blot hybridization, respectively. The results showed that the median immunohistochemical score of ADAM9 expression in OSCC tissues was significantly greater than that in normal tissues (P<0.001). Furthermore, among OSCC cases, intense staining of ADAM9 expression was detected in well-differentiated and in moderately-differentiated OSCC; ADAM9 expression was also correlated with an increased degree of cell differentiation (r=0.557; P=0.001). Expression of membrane ADAM9 was present in 3/4 cancer cell lines. Expression of active ADAM9 varied among all the tested cell lines, but significantly higher ADAM9 expression was present in certain cancer cell lines than those in HOKs (P<0.05). In summary, ADAM9 expression is enhanced in OSCC and oral cancer cell lines, suggesting its role in the pathogenesis of oral cancer. Similar to the overexpression of ADAM9 in well-differentiated prostate cancer, high degrees of ADAM9 expression have also been observed in well-differentiated OSCC.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Overexpression of ADAM9 in oral squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In agreement, overexpression of ADAM9 in lung cancer cells resulted in both brain and lung metastases, whereas mock-transfected cells only colonized the lungs (37,38). All these results are in accordance with clinical observations indicating that expression of ADAM9 was correlated with shortened survival and poor outcome of cancer patients and associated with the occurrence of distant metastases (39)(40)(41). ADAM9 was reported to be expressed by several malignancies, including renal, prostate, thyroid, gastric, breast, and non-small-cell lung cancer cells, highlighting its potentially broader importance in neoplasia (38,39,(42)(43)(44)(45)(46).…”

Section: Discussionsupporting

confidence: 85%

Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell–derived ADAM9

Mammadova‐Bach¹,

Zigrino²,

Brucker³

et al. 2016

JCI Insight

View full text Add to dashboard Cite

“…ADAM9, a member of the ADAM family, has been demonstrated to be upregulated in a range of types of human cancer, including renal cell cancer (35), prostate cancer (36), breast cancer (37), hepatocellular carcinoma (38), and pancreatic cancer (39). Previous studies have also identified miRNAs that may interact with ADAM9.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑154/ADAM9 axis inhibits the proliferation, migration and invasion of breast cancer cells

et al. 2017

View full text Add to dashboard Cite

Abstract. Breast cancer is the leading cause for cancer-associated mortality in women. Although great progress has been made in the earlier diagnosis and systemic therapy of patients with breast cancer in recent years, recurrence or distant metastasis continue to present major barriers to the successful treatment of breast cancer. Therefore, fully understanding the molecular mechanisms underlying the progression of breast cancer may be critical for the development of effective therapeutic strategies against breast cancer. The aim of the present study was to explore the expression, function and molecular mechanisms of microRNA-154 (miR-154) in human breast cancer. It was demonstrated that miR-154 was significantly downregulated in breast cancer tissue and cell lines. The restoration of miR-154 expression suppressed the proliferation, migration and invasion of breast cancer cells. ADAM metallopeptidase domain 9 (ADAM9) was identified as a novel direct target for miR-154 in breast cancer. It was demonstrated that miR-154 acted as a tumor suppressor in breast cancer by targeting ADAM9. The results of the present study suggest that the restoration of miR-154 expression may be an effective therapeutic strategy for the treatment of breast cancer in the future.

show abstract

Increased Expression of a Disintegrin and Metalloprotease-9 in Hepatocellular Carcinoma: Implications for Tumor Progression and Prognosis

Cited by 35 publications

References 24 publications

Overexpression of ADAM9 in oral squamous cell carcinoma

Overexpression of ADAM9 in oral squamous cell carcinoma

Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell–derived ADAM9

MicroRNA‑154/ADAM9 axis inhibits the proliferation, migration and invasion of breast cancer cells

Contact Info

Product

Resources

About